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Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease where substantial 
heterogeneity in clinical presentation urgently requires a better stratification of patients for the 
development of drug trials and clinical care. In this study we explored stratification through a 
crowdsourcing approach, the DREAM Prize4Life ALS Stratification Challenge. Using data from >10,000 
patients from ALS clinical trials and 1479 patients from community-based patient registers, more than 
30 teams developed new approaches for machine learning and clustering, outperforming the best 
current predictions of disease outcome. We propose a new method to integrate and analyze patient 
clusters across methods, showing a clear pattern of consistent and clinically relevant sub-groups of 
patients that also enabled the reliable classification of new patients. Our analyses reveal novel insights 
in ALS and describe for the first time the potential of a crowdsourcing to uncover hidden patient sub-
populations, and to accelerate disease understanding and therapeutic development.
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder which causes the death of motor neurons that 
control voluntary muscles, leading to progressive muscle weakening and paralysis and death within an average 
of only 3–5 years from symptom onset1. Existing therapeutic options extend survival by merely a few months2,3. 
One of the biggest challenges today is the well-established heterogeneity of ALS1,4, with patients displaying widely 
different patterns of disease manifestation and progression, and genetic analyses suggesting heterogeneity of the 
underlying biological mechanisms5–8. This heterogeneity has detrimental effects on clinical trial planning and 
interpretation3, on attempts to understand disease mechanisms, and on clinical care, as it increases uncertainty 
about prognosis and optimal treatment. Thus, successfully stratifying ALS patients into clinically meaningful 
sub-groups can be of great value for advancing the development of effective treatments and achieving better care 
for ALS patients.
Early classification systems for ALS patients were based on clinical presentation of the disease and were 
intended for ascertainment of an ALS diagnosis, but had limited capacity to predict disease prognosis or suggest 
underlying disease mechanisms4,9,10. More recent attempts towards ALS patient classification focused on predic-
tion of clinical outcomes but were often limited by small sample sizes and sparse clinical information11–14. In the 
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current study, we sought to use the power of state of the art machine learning algorithms applied to a large-scale, 
diverse and clinically detailed database of ALS patients to uncover and characterize clinically relevant subpopu-
lations of ALS patients.
Two complementary data sources were used in this challenge. The first was data from ALS national or regional 
registers from Ireland and the Piemonte and Valle d’Aosta region in Italy, representing ALS community data col-
lected as part of standard clinical visits. The second dataset was ALS clinical trial data, from the Pooled Resource 
Open-Access ALS Clinical Trials platform (PRO-ACT, www.ALSdatabase.org, developed by Prize4Life and 
Massachusetts General Hospital), an open-access database containing harmonized and de-identified data of over 
10,000 ALS patients from 23 completed clinical trials15.
The PRO-ACT database was previously used for a crowdsourcing computational challenge: The 2012 
DREAM-Phil Bowen ALS Prediction Prize4Life challenge (The ALS Prediction Challenge)16. This Challenge 
invited participants to develop computational algorithms that could predict ALS disease progression, with the 
best performing algorithms achieving a prediction accuracy that would allow a 20% reduction in the number of 
patients needed for a trial16 and are currently being tested in real-world clinical trial applications17,18.
Building upon the success of the earlier prediction challenge, the 2015 DREAM ALS Stratification Prize4Life 
Challenge (The ALS Stratification Challenge) sought to extend the scope of prediction algorithms by inviting par-
ticipants to stratify the ALS patient population into distinct clusters and develop separate predictive models for 
each subpopulation. The ALS Stratification Challenge included both disease progression and survival as predicted 
outcome measures and used both clinical trial and community-based registries data. A prize of $28,000, collected 
through a crowdfunding effort, was offered to best performing algorithms (see Supplementary material part 1 and 
2 for detailed description of both datasets and the challenge description as given to participants, respectively).
In this publication we describe the results of the challenge including analysis of the best performing algo-
rithms’ performance and methods, as well as novel methods to uncover the patient sub-populations, their statis-
tical significance and relative importance of different predictive features obtained from cross-model assessment.
Results
Challenge outline. The ALS Stratification Challenge was developed and ran through a collaboration between 
the nonprofit organizations Dialogue for Reverse Engineering Assessments and Methods initiative (DREAM, 
http://dreamchallenges.org/) and Prize4Life (www.prize4life.org.il) using the Sage Bionetworks Synapse platform 
(www.synapse.org). The challenge ran between June and October 2015 and drew 288 registrants, eventually lead-
ing to final submissions by 30 teams (88 individual participants) from 15 countries (see Supplementary material 
part 3 for participant survey).
The challenge was based on two datasets: (1) ALS clinical trials data collected through the PRO-ACT database, 
and (2) community-based ALS clinical data collected through ALS registries. Both datasets contained longitudi-
nally sampled demographic and clinical information with some additional genetic (specific mutation) and family 
history data in the registries and detailed laboratory tests in PRO-ACT (See Supplementary material part 1 and 2). 
We solicited predictions across four sub-challenges, namely of (1) disease progression or (2) survival probability 
using PRO-ACT data and (3) disease progression or (4) survival probability using ALS registries data.
Challenge participants were asked to use patients’ data from the first 3 months of records to predict disease 
progression at 12 months or probability of survival at 12, 18 & 24 months. Disease progression was defined as the 
slope of the ALS Functional Rating Scale (ALSFRS or ALSFRS-R) between 3 and 12 months (see online methods). 
To avoid overfitting of algorithms19, data from the publicly available PRO-ACT database was used as the training 
set, and a separate set of data from six additional clinical trials, which were not previously publicly available, was 
used for validation. The registry data, which was never before made publicly available, was divided randomly 
(split evenly across the two registries) into training and validation sets.
The challenge introduced an additional requirement that predictions are limited in the number of used clinical 
features (Fig. 1). The requirement for limiting the number of features was highlighted by our clinical advisors to 
facilitate the application of predictive algorithms in natural clinical setting13. A preliminary analysis indicated the 
benefit from clustering (in terms of improved prediction accuracy) tends to increase when the number of features 
Figure 1. Outline of algorithms design. Algorithms used either PRO-ACT or ALS registries data, and first (1) 
applied various data pre-processing and imputation methods. Next, (2) algorithms could cluster the patient 
population into any number of sub-groups and (3) select the most informative features for each cluster (up to a 
maximum of 6 features). Then (4) a “predictor” component had to use values of the selected features to predict 
either disease progression or survival for any given patient. In the scoring of the challenge, the algorithms made 
predictions for patients that were not part of the original datasets available for algorithms training, and the 
accuracy of these predictions was assessed.
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is restricted, and this effect plateaued at around 6 features (see Supplementary material part 4). Thus, participants 
were asked to write algorithms that first selected the most informative features (up to 6 features), and in a second 
step used only the data from these selected features to make progression or survival predictions (Fig. 1).
To enforce the separation between these steps we required participants to implement their algorithms 
in Docker containers (https://docs.docker.com) executed on the IBM Z cloud (https://www.ibm.com/
it-infrastructure/z/capabilities/enterprise-security). Algorithms were thus run in a secured environment where 
the participants could not see the validation data or other jobs.
Comparative assessment of prediction methods. In general, the top performing teams in each 
sub-challenge (except for the registry progression sub-challenge) significantly outperformed the best base-
line algorithm (Fig. 2, See Supplementary material part 5 for full results). Random forest was by far the most 
commonly used prediction method, with overall very good results, scoring among the first three ranks in 
each subchallenge (Fig. 2). It was the method used by the best performing team in the registry progression 
sub-challenge and by most algorithms ranked between the 2nd and 8th places across all four sub-challenges 
(Fig. 2). Another successful method included a Gaussian process regression model with an arithmetic mean ker-
nel, which was the best performing for the two survival challenges but did not perform so well for the progression 
challenges.
The performance of the top teams, as was observed in other crowdsourcing challenges20,21, varied substantially 
even if the same machine learning method was used, and depended to a large extend on data pre-processing, 
especially feature selection and representation of time-resolved features. Here, the best performing teams repre-
sented time-resolved information by a combination of simple summary statistics (for instance minimum, max-
imum and average of the feature values). For feature selection, the best teams evaluated the contribution of the 
complete set of selected features (as opposed to selecting them one by one), for example through evaluating sets 
of features by their combined information gain or by aggregating their weight along the paths of all trees in a 
random forest.
Survival predictions deserve special consideration, as one team substantially out-performed other partici-
pants in both sub-challenges. Survival predictions are particularly challenging due to the right-censored outcome 
variable survival time: data can be terminated by either patient death or by trial drop out. The standard Cox 
proportional hazards model, routinely used to explore the dependency between clinical features and survival, 
ignores such censored cases. In the current challenge, Yuanfang Guan generalized this right censored problem 
via a novel strategy GuanRank by complete ranking of training examples regardless of the censoring status, ena-
bling GuanRank to be built-in to any base-learners (in this case, Gaussian Process Regression)22. This defined 
the outcome variable more precisely, which led to a more adequate training of regression models (here: Gaussian 
process models) explaining the algorithm’s superior prediction performance. Indeed, the strategy outperformed 
a standard Cox model by 20% accuracy22, and outperformed the respective second best team in 98.4% and 99.4% 
of the bootstrap samples (in the PROACT and registry subchallenges, respectively, compare Fig. 2).
Notably, for the sub-challenges running on the PRO-ACT database, the best performing algorithms signifi-
cantly outperformed the winning method from the first challenge16. This is even more noteworthy given that the 
Figure 2. Overview of the performance of submitted and baseline algorithms across the four sub-challenges. 
Submissions were assessed by Z-scores combining RMSD, concordance index and Pearson’s correlation 
(see online methods for details on validation and testing). Performance was also compared to two baseline 
algorithms which were based on the top performing prediction algorithms submitted to the 2012 ALS 
prediction challenge, adapted to the requirements of the new challenge (see Supplementary material part 4). 
Grey boxes denote the performance of the best-performing baseline algorithm (left and right boundary of the 
box represent intervals of its performance ± the bootstrapped standard deviation). Teams that achieved the 
top three scores in any sub-challenge are indicated by colored symbols and shown by the same symbol in all 
sub-challenges. The BT score (right side of the figure) denotes the percentage of bootstrap samples where the 
top ranking team outperformed the second ranking team. The underlying method is indicated (RF = random 
forest, GBM = generalized boosting model, Cox = Cox model, GR = Gaussian regression). Submissions based 
on random forests, the most frequently used method, are denoted by symbols with dashed outlines.
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validation set was not randomly divided from the training set, but actually included the more difficult and realis-
tic criteria of application of the algorithms to a data comprising of six new never used before trials.
Predictive clinical features. The challenge’s requirement of using only up to six features for prediction 
encouraged participants to identify the most informative features for prediction of disease progression or sur-
vival (Fig. 3). The most frequently used features across all sub-challenges were those that are well described in 
the literature as being strongly related to ALS prognosis: time from disease onset and total ALSFRS score23–25. 
Age and gender were more informative for predicting survival rather than disease progression, in line with liter-
ature22–24,26–28. While age and gender were generally predictive in this data as well, they were not specifically more 
predictive for one particular subgroup of patients, and therefore less relevant for stratification. Bulbar function is 
also known to be particularly informative for clinical outcome prediction24–26 and ALSFRS questions 1 and 3 (bul-
bar functions) were selected more frequently compared to any other functional domains across all sub-challenges. 
Interestingly, ALSFRS question Q2 (salivation) was rarely used, in line with previous works indicating this ques-
tion might be less well correlated with total ALSFRS scores and/or disease progression, due to effective available 
treatment options29.
Data availability was another important factor for feature selection. For example, while weight or BMI, known 
to correlate with ALS prognosis30,31, was frequently selected for predictions for the PRO-ACT dataset, it was 
recorded in only < 10% of the cases in the registry data, making it unusable for predictions (Fig. 3). Similar 
potential predictive benefit of features was observed with respect to features evaluating breathing capacity, which 
is the main cause of death for ALS patients32, but not routinely collected for registry patients. This suggests that 
clinicians could potentially improve their insight into individual patient prognosis by incorporating a few rather 
accessible measures into routine clinical monitoring (relevant features are bolded in Fig. 3). Indeed, since the 
challenge ran, clinics involved in the Italian registry used in this challenge have been careful to add measurements 
of patient weight, BMI and respiratory functions.
Clinically relevant patient clusters. In this challenge we used a crowdsourcing approach to explore differ-
ent stratification schemes for ALS patients and use them to identify clinically significant patient sub-populations. 
The main goal of stratification, however, was not necessarily to impact prediction accuracy, and indeed we did not 
Figure 3. Overview of the features most frequently used by the algorithms within and across subchallenges. For 
each subchallenge, we assessed the number of times each feature was used for prediction across all submitted 
algorithms (shown as probability. The features are ranked-ordered by this probability, averaged across all sub-
challenges where darker colors denote lower probabilities). Cases where a given feature was not used at all 
for a given sub-challenge are shown in grey (probability 0). Features that are recommended to be assessed by 
clinicians more often to aid prognosis are marked in bold.
www.nature.com/scientificreports/
5SCIENTIFIC RePoRtS |           (2019) 9:690  | DOI:10.1038/s41598-018-36873-4
observe any consistent advantage (in terms of improved prediction accuracy) for clustering in any of the evalu-
ation metrics. Instead, as described in the following, we developed novel strategies utilizing this crowdsourcing 
approach to reveal, across a large variety of methods, consistent clusters of patients, to support understanding the 
ALS pathology, improving clinical care and planning better, more efficient clinical trials. This sort of analysis can 
only be accomplished in the context of a large communal effort that allows comparison of independently designed 
algorithms working on sufficiently large datasets, as was the case in this challenge.
In comparison, individual clustering methods led to heterogeneous results and the numbers of clusters per 
method varied from 2 to more than 100. Integrating clustering across a large variety of methods on the other 
hand, revealed a small set of discrete consensus clusters (Fig. 4, see online methods). In both sub-challenges based 
on PRO-ACT, patients within consensus clusters were significantly more strongly connected than expected by 
chance (pairs of patients co-clustered significantly with FDR < 5% are depicted as edges in Fig. 4b). The stronger 
clustering effect in the PRO-ACT vs. the registry sub-challenges is likely a reflection of sample size (10,000 + vs. 
~1,500 patients, respectively).
Overall, consensus clusters could be broadly regarded as classifying patients as slow progressing (“red”), fast 
progressing (“blue”), early stage (“purple”) or late stage (“green”). We chose to focus on clinical characteristics of 
the PRO-ACT progression sub-challenge, since these consensus clusters reached the highest level of statistical 
significance, but similar clusters were found across all sub-challenges.
In order to demonstrate how the identified clusters can be utilized in a clinical setup, we also examined 
whether new patients can be assigned into their respective cluster reliably. By using the most significant 20 fea-
tures (FDR < 0.01%) we were able to re-associate 84% of the core patients (the patients closest to their respective 
cluster center, compare Fig. 4). Note, that the consensus clustering that was derived solely from the participants 
clustering, while the re-clustering is solely based on the values of the clinical features (see online methods). In 
other words, based on the commonalities of the methods generated by separate teams we were able to uncover 
a network of sub-groups that can be recreated with good success, strongly suggesting clinical usability in a field 
where patient stratification is pivotal to development of an effective ALS treatment.
In the following, we characterize these clusters and describe the relationship between patient strata and the 
most discriminative clinical features: One cluster, the “red” or “slow progressing” cluster included patients who, 
despite having experienced symptoms for a relatively long time (2.2 years from disease onset, on average) still 
maintained relatively high functional capabilities (average ALSFRS-R scores of 40.25 at the beginning of the 
clinical observation period), with functional impairments mostly limited to limbs and little bulbar or respira-
tory involvement. Accordingly, these patients had slow disease progression (annual average loss of −0.48 on the 
ALSFRS-R scale). These are the patients with the best prognosis for ALS and therefore merit closer investigation, 
as they might hold clues for clinical or biological features underlying enhanced resilience. First, only few (3%) 
of these “slow progressing” patients had bulbar onset. While bulbar onset had been frequently correlated with 
poorer prognosis22–24, this cluster analysis suggests that bulbar patients will rarely be classified as a slow progress-
ing disease presentation. A second important observation is low creatinine levels (average of 67 mcmol/L in the 
first three month of data collection, which is considered abnormally low level compared to the desired range of 
Figure 4. Overview of the consensus clustering. (a) Outline of consensus clustering method: the tendency 
of patients to co-cluster was assessed across cluster-sets generated independently by the different solvers 
(I). The resulting connectivity matrix (II) was then used as input for obtaining consensus clusters (III) by 
k-means. Finally, False discovery rates (FDRs) were estimated by ANOVA (IV) on 100 randomized datasets 
to assess, which features were differentially distributed between consensus clusters, see online methods and 
Supplementary material part 6. (b) Graph-based clustering of the connectivity matrix for the PRO-ACT 
progression sub-challenge. Nodes in the graph represent patients and are colored based on their k-means 
cluster, if they correspond to the 50% of “core” patients closest to their respective cluster centroid. Edges 
denote pairs of patients with a significant chance of being co-clustered by solvers. (c) We compared features 
(names starting with Q/R are ALSFRS component scores from the original or revised scale) between pairs of 
clusters (columns in heatmap) by t-tests/FDRs. Different colors within heatmap rows indicate values that are 
significantly different between clusters (FDR < 5%) on the scale from the lowest (blue) to highest (red). Notable 
results are listed explicitly in Panel b.
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74.3–107mcmol/L). Creatinine was reported as a predictor in the previous challenge16, and these results suggest 
that it might also serve as a predictor of this special case of patients with improved prognosis.
A very similar cluster was observed in the analysis of clusters derived from the PRO-ACT survival 
sub-challenge, with patients living with ALS for an average of 1.5 years while displaying little functional decline 
(average total ALSFRS-R score 39.4), largely intact breathing functionality (FVC 94.4% of normal on average) and 
an ALSFRS progression rate of −0.72 points/months.
To characterize clusters and the involved patients for clinical relevance, we compared all pairs of clusters 
(using ANOVA and t-test, resulting in multiple-testing corrected false discovery rates or FDRs) to assess which 
features had values specifically different between the clusters (Fig. 4c). We also examined the correlation between 
feature values and clinical outcome (progression rate) in each cluster to identify features which were important 
for prediction in some clusters but not in others. Based on the clusters clinical features analysis, the two features 
unique for this “slow progressing” cluster were urine creatinine and segmented neutrophils (Fig. 4b,c). Both of 
these features are therefore potential biomarkers of slow progression in ALS. Neutrophils were indeed found to 
be connected to ALS progression in some studies33,34 but not others35 and the stratification to sub-groups might 
shed further light on these results.
Another cluster that was superficially similar but in fact quite different was the “purple” or “early stage 
patients”. In our pair-wise comparison of features across clusters, the “early stage” and “slow progression” clusters 
(“purple” and “red” clusters respectively) were similar in having high ALSFRS-R and FVC scores in the first 3 
months of assessment, indicating little functional impairment (Fig. 4b,c). However, the distinctive feature of 
patients in the “purple” cluster was the fact that they were early in their disease, on average ~10 months from 
symptom onset. Thus, the largely preserved functional state of these patients could be attributed to their early 
disease stage, rather than a slow progression rate. Indeed, with time these patients became fast progressors (−0.93 
ALSAFRS-R points decline monthly on average) and had marginally lower than normal creatinine levels (72.25 
mcmol/L on average on the first three months of data). Curiously, urine creatinine was correlated with disease 
progression (r2 = 0.467 p = 0.01, see Supplementary material 7 for figures) only for this cluster, suggesting again 
that urine creatinine might be useful predictor of disease progression already early in the disease. The relationship 
between urine creatinine and serum creatinine and with both to muscle breakdown is not straight forward36. The 
correlations to creatinine and Urine creatinine in the “red” (slow progressors) and “purple” (early patient) clus-
ter suggests a scheme to enable early stage assessment of expected disease progression that can aid clinical trial 
recruitment and clinical care planning, both highly needed early in the disease.
A third “green” cluster of “late stage” patients included patients that were clinically advanced in their disease 
while being, on average, only 1.7 years from disease onset. These patients were severely disabled in all functional 
domains (average ALSFRS-R score of 29 points at the beginning of the clinical observation period) and were dis-
playing early signs of breathing dysfunction (average FVC 77%) and shorter survival time (1.5 years on average 
from first recording time, with an average disease duration of 3.2 y).
These patients had a significant correlation between their ALSFRS “trunk” score (questions about dressing 
and hygiene and turning in bed) and disease progression (r2 = 0.314, p = 0.001), which might be indicative of 
their advanced disability status. A second feature unique predictive for this cluster was Slow Vital Capacity (SVC) 
(Fig. 4c, examples for both features are available in Supplementary material part 7). These two classifiers should 
be taken into consideration clinically as they might be stronger indicators that the patients are reaching the final 
stages of their disease. The “trunk” score indeed represents complex functions that require the combined efforts 
of upper and lower motor neurons, and is therefore more clearly impaired later in the disease. SVC, while highly 
correlated with FVC, might become predictive later in the disease when respiratory function diminishes. They 
could also be used for clinical trial exclusion criteria to improve patient survival throughout the trial. Indeed, SVC 
was recently suggested as an indicator of respiratory failure in ALS37.
The last cluster, “blue” or “fast progressing” patients, represents the most critical patients, who have been 
experiencing symptoms for only 10 months on average, but were already significantly impaired in all functional 
categories (average ALSFRS-R score of 35.75) at the beginning of the clinical observation period. These patients 
continue to have a very fast disease progression rate (ALSFRS progression slope of −1.05points/month) and an 
overall average survival of only 2.7 years from disease onset. Half of the patients in this cluster had bulbar onset 
(compared to 20% bulbar onset across all patients) and were more likely to have lower scores in all ALSFRS-R 
functional domains (leg, hand, trunk, bulbar and respiratory functions) and to have significant weight loss over 
the 1-year observation period (average of 5 kg lost per year).
Importantly, a similar yet more severe cluster was observed in the PRO-ACT survival data, with patients 
showing diminished disease states (initial ALSFRS-R of 24 ALSFRS points) and survival (average of 443 days 
from trial onset). Women were more likely to be fast progressors, making up 53% of this cluster, compared to 40% 
women across all clusters, even beyond their higher likelihood to have bulbar onset (32% of women). This cluster 
of patients with the poorest prognosis was also found in the registry consensus clustering for both the progression 
and the survival data.
When looking at features that were significantly different between almost all pairs of clusters, a noticeable 
observation is the discriminative power of ALSFRS question 1 (speech) and the combined “mouth” measure 
(averaging ALSFRS questions 1–3), highlighting again the important role of bulbar function in discriminating 
ALS consensus clusters. Overall this cluster helps integrate information, some already accepted (such as the asso-
ciation of bulbar onset and respiratory signs with poorer prognosis) and some suggested (the potential predictive 
roles of creatinine, urine creatinine, neutrophil and others) in a statistically supported unified framework, ena-
bling discerning fast and slow progressing patients earlier in their disease course, as well as markers helping to 
identify patient reaching the final stages of their disease.
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Discussion
Disease heterogeneity, and particularly large unexplained variance in disease progression rate and survival, is 
a hallmark feature of ALS disease38. The hypothesized existence of distinct subgroups of ALS patients and their 
importance for ALS research and clinical care were highlighted in recent years by clinical trials in which only a 
subset of patients responded to the tested treatment3,39. Despite some recent advances from genetic studies40,41, 
there is currently no generally accepted stratification scheme for ALS patients, and more importantly, no con-
sistent way to tailor survival and disease progression estimates to individual patients. The ALS Stratification 
Challenge was a global crowdsourcing effort aimed to develop new tools and insights for understanding patient 
subpopulations as they relate to ALS disease progression and survival. Thirty teams submitted algorithms to the 
challenge, with the winning solutions outperforming currently available prediction algorithms (adapted from the 
previous ALS Prediction challenge)16.
Compared to the ALS Prediction Challenge16, the current challenge included additional data and design fea-
tures that made its resulting algorithms more robust and more relevant for clinical application, including the use 
of community-based data, the limitation on the number of features used for prediction, and the prediction of 
survival as well as disease progression. Another requirement highly relevant to the application for future clinical 
trials: the validation of algorithms on a dataset derived from completely independent clinical trials.
The current challenge invited participants to develop prediction algorithms either based on clinical trial data 
or from ALS registries containing data collected through ALS clinics. This is the first time that registry data was 
made publicly available, and the design of the challenge enabled us to directly compare performance of prediction 
algorithms when applied to PRO-ACT vs. registry data. We suggest a number of clinical features (Fig. 3), such as 
FVC and weight, which could be added to routine clinical assessment to potentially improve prediction accuracy 
and aid clinicians in predicting individual patient prognosis. Conversely, a number of features that could be found 
exclusively in the registries data, including common genetic mutation data and detailed onset site assessments, 
were both highly informative for prediction and should be considered for incorporation into ALS clinical trial 
screening or baseline assessment.
The main goal of this challenge was to uncover clinically meaningful subgroups of ALS patients, a challeng-
ing task since no known “ground truth” exists for ALS patient stratification. In this study we designed a novel 
“bottom-up” method for the identification of consensus patient clusters and the determination of discriminating 
features (see online methods). We did not make any a-priori assumptions regarding patient sub-populations, but 
instead defined patient clusters by a “consensus vote” based on participants’ submitted algorithms. Challenge par-
ticipants were free to base their clustering on any subset of the available clinical data, choose any type of clustering 
method and any number of clusters. While clustering was not strongly related to immediate benefit in algorithms’ 
prediction accuracy, it did reveal consistent patterns of patient classification that are of great clinical interest and 
that was robust enough to enable classification of new patients with high degree of success. We suggest that these 
clusters could be used to identify subgroups of patients to guide further research of disease mechanisms and the 
planning of individual patient care programs and ALS clinical trials. As most clinical trials aim to enroll patients 
early in their disease to ensure a sufficient therapeutic window, separating patients that will be slow or fast pro-
gressors early is critical to enable correct clinical trial development and interpretation. Similarly, signed of end of 
life in patients can aid patient decision making and clinical care substantially.
The results of this study can help accelerate disease understanding in several ways: the stratification scheme 
suggested in this analysis offers novel insights that can integrated in the development of novel ALS therapeutics, 
aiding patient selection and result interpretation. Novel differentiating features such as creatinine or SVC can also 
help shed light on mechanisms related to disease progression, as well as mechanisms related specifically to end of 
life in ALS, a topic of critical clinical importance. Ideally, in the future, clinical data such as described here would 
be further integrated with data obtained from different types of high-throughput technologies (such as transcrip-
tomic, genomics, metabolomics), allowing for the identification of predictive biomarkers for early diagnosis and 
treatments. Several such highly needed large scale initiatives are being developed now42.
Given the covert nature of ALS patient stratification, only a large-scale crowdsourcing effort, where differ-
ent and independent teams apply diverse methods on a similar and large enough dataset can uncover such an 
underlying population structure free from a-priory assumptions. This communal approach indeed revealed a few 
sub-groups of patients which not only tended to cluster together across different algorithms but also displayed 
similar characteristics across different sub-challenges - clusters which may be the basis for a new stratification 
framework for ALS patients. Overall, we could significantly differentiate four patient groups: slow progressing 
patient and fast progressing patients, as well as patients with an average progression rate which were either early 
or late in their disease at the beginning of the recorded clinical observation period.
We examined the features most often chosen for prediction by the different challenge participants to assess 
their predictive power. This analysis revealed several features that could help classify patients into sub-groups. 
While some features are already well described, such as age, gender22–24 and respiratory capacity.22,29,43–45 and 
other, such as limb motor function, specific ALSFRS-R scores46 and creatinine16,29,47–49 and specific ALS staging 
scores were at least suggested as predictive, our results not only supported these findings but help put them in to 
a more usable and testable context. For example, creatinine was found to be predictive specifically for patients 
early in their disease. Segmented neutrophils were also suggested by our analysis as a relevant novel predictor, 
specifically for slower progressing patients, while SVC and ALSFRS “trunk” scores were associated with outcomes 
only specifically for patients later in their disease.
Overall, these results suggest a novel stratification scheme for ALS, with relevant classifiers and group-specific 
predictors. Stratification is highly needed to advance clinical development, for clinical care and to allow more 
personalized treatment. The tools and insights presented in this study can offer a first attempt for improvement 
in clinical trial development, selection and interpretation, accelerating the development of a much-needed 
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treatment for a dire aliment such as ALS. More broadly they open the door to a new avenue of research using 
crowdsourcing approaches to uncover patient sub-groups unattainable by other means.
Methods
Datasets. The challenge made use of two datasets: data collected during clinical trials (PRO-ACT) and data 
collected during routine visits to ALS clinics (ALS registries). Both datasets included both static and time resolved 
measurements covering a wide range of data types and clinical measurements (full data dictionaries for both 
datasets can be found in the supplementary material). The time in which measurements were taken was noted 
in days relative to clinical trial onset or to first clinic visit available on records (time “delta”). Data was provided 
to challenge participants in tabular form. Each line represented the measurement of a single feature for a single 
patient at a particular time point Outcome measures (ALSFRS slope for progression and survival) for the training 
datasets were provided to challenge participants in separate tables.
PRO-ACT. The Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) Database was formed in 2011 by 
Prize4Life in collaboration with the Neurological Clinical Research Institute (NCRI) of Massachusetts General 
Hospital, the Northeast ALS Consortium, and with funding from the ALS Therapy Alliance. PRO-ACT con-
tains data collected during phase II/III ALS clinical trial, volunteered by PRO-ACT Consortium members. Data 
from 17 clinical trials15 was used for the previous prediction challenge16 and later made publicly available via the 
PRO-ACT web platform (www.ALSdatabase.org). This data was used for algorithms’ training in the current chal-
lenge. Data from 6 additional clinical trials50–55, never before made publicly available, was homogenized to comply 
with PRO-ACT data format standards and used for algorithms’ validation and assessment. Similar to the design 
of the previous challenge, the data used for validation was randomly subdivided into a test set (leaderboard data, 
400 patients) and a validation set (1,488 patients). Challenge participant could submit versions of their code to be 
tested on the test set (limited to once per week per team to avoid overfitting) with the results published on a public 
leaderboard which served to provide feedback to participants. After the challenge was completed all submitted 
algorithms were assessed using the validation set data (see main manuscript, Fig. 2).
ALS registries data. Community-based data, never before publicly released, used in this challenge was col-
lected through two ALS registries: 1) The Irish National ALS Register including data collected from ALS clinics 
in Ireland. 2) The Piemonte and Valle d’Aosta Register for ALS, including data collected from ALS clinics in 
Piemonte and Valle d’Aosta region of Italy. Data from the two registries was merged, harmonized and converted to 
the same format as the PRO-ACT data. Data was divided into a training (986 patients) and a validation (493) set. 
Stratification of data ensured a similarly proportional representation of patients from the Irish and Italian cohorts 
but was otherwise done randomly. Due to the small number of patients available in this dataset there was no test 
set (leaderboard data) available to challenge participants.
Definition of predicted outcome measures - “ground truth” calculation. Disease progression. 
ALS disease progression was defined as the slope of the total ALSFRS score, similar to the definitions used in the 
2012 prediction challenge16. Briefly, ALSFRS was calculated as:
−
−
ALSFRS t ALSFRS t
t t
( ) ( )2 1
2 1
where t1 and t2 were the time points at the first and last clinic records in the relevant time period 92–365 days in 
which total ALSFRS scores were recorded. Whereas time data in the both challenge datasets was given in days, it 
was converted to months for the calculation of ALSFRS slope, according to the following: t(months) = (t(days)/365) 
*12). Patients had to have at least two clinical records in the relevant time period for their data to be used for 
validation. Participants were required to write algorithms that would predict ALSFRS slope between 3 and 12 
months, based on data collected in the first three months of clinical records.
Survival. Survival was defined as time until death or until tracheostomy surgery (the introduction of invasive 
breathing tube- time where without intervention the patient was unlikely to survive), whenever this information 
was available. For patients who had no time of death logged on the clinical records the time of the last clinical visit 
was recorded in the survival records with a status indicating they were alive.
Patients whose final records were on or before day 90 (from onset of clinical trial or of clinical records) were 
excluded from the survival analysis. Challenge participants were required to write algorithms that predicted the 
likelihood of survival for each patient at three time points; 12, 18 and 24 months from the onset of clinical records.
Predictions assessment and scoring scheme. All methods for performance assessment were based on 
evaluating how close the algorithms’ predictions were compared to the respective ground truth, averaged across 
all patients. We used three different evaluation metrics to assess submitted algorithms’ performance in the disease 
progression sub-challenges. Two methods, the root mean square deviation (RMSD) and Pearson’s correlation 
(PCC) were used and described in the previous ALS prediction challenge16. In the current challenge we added a 
third evaluation metric: the concordance index (CI), which evaluates the similarity of ranks between predicted 
and actual ordered lists of measurements. The concordance index was the only metric used to evaluate perfor-
mance in the survival prediction sub-challenge, since it is commonly used in survival analysis and is best suited 
for assessing censored data56. When there is no censored data or ties, the c-index between a predicted list of sur-
vival times of n patients, = …Pred p p p{ , , , }n1 2 , and the actual survival times for the same n patients, 
= …Actual a a a{ , , , }n1 2 , is calculated as:
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Please see supplementary data on details accommodating for the possibilities of ties and censored data.
The three performance assessment scores (or three CI values, in the case of survival prediction) were com-
bined using Z-score transformation. We generated 100,000 random sets of predictions for each of the four 
sub-challenges, by shuffling the assignment of “ground truth” progression or survival values to patients. We then 
calculated the RMSD, PCC and CI scores for each of these random shuffles and used the resulting three sets of 
100,000 values to calculate the mean and standard deviation (SD) of each of the three scoring metrics. These 
mean and SD values were used to calculate the Z-scores for the three assessment metrics for each of the submitted 
algorithms, given by:
= −z score mean SD( )/score
= + − = + +z z z z z z z z,slope CI PCC RMSD survival 12 18 24
Outcomes of the survival sub-challenges were further validated by a receiver operating characteristic analysis 
(time ROC analysis). For the purpose of the challenge, time ROC was calculated using the R-package timeROC 
(https://cran.r-project.org/web/packages/timeROC/timeROC.pdf). On the plus side, the timeROC analysis 
incorporated the three survival time frames to be predicted (12, 18, 24 months), and performance is thus specific 
to the time frame in contrast to the analysis via CI, where the same set of predictions would evaluate the same 
irrespective to the time frame. However, the CI is better suited to represent the right censured nature of the sur-
vival data. The rank ordering of submitted algorithms for both survival sub-challenges was very similar when 
comparing the outcomes of the combined z-transformed CI index and the time ROC analysis. Results of the time 
ROC analysis could be found in the supplementary material.
Consensus clusters and determination of discriminating features. For each subchallenge, we inte-
grated the teams’ clustering into a consensus clustering. First, we created a square patient x patient co-clustering 
matrix M where each matrix element mi,j contained a normalized score that expressed how often the correspond-
ing patients i and j appear together in a single cluster across all team submissions. The normalized score takes the 
size of the teams’ clusters into account such that two patients clustered together in a smaller cluster receive a larger 
weight. The scores mi,j were calculated as the sum of contributions (eq. 1), across all submissions s, where patients 
i and j appear together in the same cluster:
∑= =m
p
C
if i j in the same cluster in S otherwise_ log , ; 0 ,i j s
size s
s
, 1
where p is the total number of patients in the given sub-challenge and cs is the number of patients in the cluster of 
submission s that includes both i and j (to normalize by cluster size).
We next determined the statistical significance of mi,j values, i.e. to determine whether patients i and j are 
clustered together more often than expected by chance. We randomly assigned patients into clusters of the same 
size as contained in the original submissions and repeated this random sampling process 100 times. We then 
calculated mi,j scores for each set of randomly assigned clusters, giving us 100 mi,j scores for each i, j patient pair. 
We used these permuted mi,j value to calculate a false discovery rate for any given mi,j score derived from the par-
ticipants’ submissions data, by assigning:
=
∗ ∗
FDR i j
N N
N
( , )
100 perm true
false
where Nperm is the number of permutations, Ntrue and Nfalse refer to the number of scores computed from submitted 
and permuted data, respectively, that were less or equal than the given score. This approach to FDR calculation 
was adapted from significance analysis of microarrays57 and described in detail in previous work58. Subsequently 
a FDR threshold of 5% was applied to identify significantly pairs of patients that significantly tend to be clustered 
together.
A graph of significant pairs was then plotted using the graphviz software package in order to visually deter-
mine a plausible number of clusters k. To generate the final patient clusters, we performed k-means clustering 
for k clusters based on the matrix M using average linkage and Pearson’s correlation metric. Thus, the correlation 
metric calculates the distance between patients i and j by comparing the corresponding rows, denoted as mi and 
mj, in the matrix M. This analysis identified three consensus clusters for both survival and the registry progression 
sub-challenges and four clusters for the PROACT progression sub-challenge.
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Detection of features differentially distributed across patient groups. After finding a small num-
ber of consensus clusters of patients for each sub-challenge, we determined the features that discriminate between 
consensus clusters by statistical tests. Values of longitudinal variables (e.g., ALSFRS) were averaged across time, 
and we looked at average values of two different time periods consistent with the challenge’s overall design: 0–3 
months and 3–12 months. We applied one-way analysis of variance (ANOVA) to continuous features (e.g. age 
of onset) and Fisher’s exact test to discrete features (e.g. site of onset). This leads to two matrices, C and D, cap-
turing the values of the continuous and discrete features, respectively. Rows in these matrices correspond to the 
features, columns to the patients. In addition, each feature vector (containing the values for that feature across 
the p patients) was randomly permuted a hundred times and statistical tests were applied to the 100 randomized 
datasets to compute FDRs (analogous to the description above) separately for the results from Fisher’s exact test 
and ANOVA.
We then regard the relative ranks from the ANOVA and Fisher as new test values. From these, we compute 
FDRs now across discrete and continuous features together. By this integrated statistical assessment, we obtained 
FDR values for all features. Features were deemed statistically significant across all clusters if they exhibited FDR 
values of <5%. See below pseudo code (Fig. 5) for details.
Subsequently, t-tests were applied to identify all pairs of clusters where ANOVA determined that continuous 
features exhibited significantly differential values (FDR < 5%). The same permutations were applied to the fea-
ture vectors as above, such that we were able to transform t-test p-values into false discovery rates analogously. 
As before, we regard a feature as statistically significantly different between two clusters if such a comparison 
resulted in an FDR <5%. FDRs do not need multiple testing correction as it is already built into the permutation 
test. Note that we applied the ANOVA “trick” here: pairwise comparisons were only performed (and thus subject 
to multiple testing correction) for features with overall significance across all clusters. This leads to a less severe 
multiple testing correction and accordingly to a more sensitive test for the pairwise comparisons in contrast to the 
case were pairwise comparisons would have been performed and corrected for all features.
In order to summarize the differences between the clusters more succinctly, we aimed to integrate the pairwise 
comparisons, by collapsing the metrics based on pairs of clusters into a metrics based on individual clusters. We 
created a simple rank order statistics for each feature and cluster by counting pairwise comparisons in the follow-
ing way: If a comparison between a pair of clusters (a, b) is significant, and the given feature displays higher values 
Figure 5. Pseudo code analysis of differentially distributed features. The pseudocode in the left panel illustrates 
the computation of the ANOVA test statistic a at the example of the continuous features in C. The design g 
specifies the mapping of patients to clusters. A permuted test is calculated by shuffling values in rows of the 
matrix C 100 times, computing their associated test statistics a’ and pushing their relative ranks and the relative 
ranks of a separately into arrays r’ and r, respectively. The backslash notation denotes the removal of an element, 
i.e. in a’ = a’\max(a’), the entry with the highest value is removed from a’. Analogously, the Fisher test statistic 
f is calculated for the discrete features in D (pseudo code in the right panel). Finally, FDRs are calculated by 
comparing the relative ranks from the true statistics r vs. the relative ranks from the permuted statistics r’ across 
discrete and continuous features (pseudocode in lower panel).
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in a as compared to b, we increase the rank of a via r(a) = r(a) + 1 and decrease the rank of b via r(b) = r(b) − 1. 
After all pairwise comparisons are integrated, a heatmap is created (Fig. 4c) by linearly scaling each feature to [−1 
… +1] range.
Assignment of patients to consensus clusters (re-clustering). The purpose of re-clustering is to 
assign new patients to the previously defined consensus clusters. While the consensus clusters were derived based 
on the submissions of the individual challenge participants, the re-clustering is based on the values of the fea-
tures, i.e. new patients are assigned to clusters where feature values of patients and average feature values of the 
consensus clusters match best. The features to be matched are those features previously determined to be discrim-
inating. The procedure involves two steps, (1) normalization of feature values and (2) matching. Feature values 
are normalized by subtracting the average and dividing by the standard deviation of each feature, i.e. they are 
transformed into z-scores. Subsequently, patients are tested against the averaged and z-score normalized feature 
vector of each consensus cluster via the uncentered correlation. Each patient is then assigned to the cluster that 
resulted in the highest value of the uncentered correlation. A tenfold cross validation (10CV) has been applied 
to determine assignment accuracy. Here, 10% of all patients (CV test set) have been removed in each step of CV 
before differentiating features were determined. After doing this 10 times, accuracy was determined based on the 
assignment of patients across the 10 test sets.
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